drugset / Trial / NCT05445557
Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks
RandomizedParallel-groupTriple-blindTreatment
Summary
A total of 12 subjects will be injected with RZL-012 and placebo. Each of the subject's flanks will be randomized for each of the treatment. A total of 24 flanks will be randomized in the double blind phase. They will be monitored for safety and efficacy for 12 weeks. After codes opening, a second treatment cycle on the previously untreated contralateral flank will be done. Subjects will be monitored for safety and efficacy for additional 12 weeks.
Timeline
- Start
- 2022-03-10
- Primary completion
- 2022-10-20
- Completion
- 2022-11-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | UTENPANIUM | Small molecule | 7.5 mg | Other |
Indications
No indication recorded.